
CLAIMS

1. A compound of Formula I:



I

stereoisomers or a pharmaceutically acceptable salt thereof, wherein:

A is CR^3;

B and D are ~~independently~~ CR^{15};

one R^1 is halogen and the other R^1 is halogen, C_1-C_3 alkyl, C_3-C_4 cycloalkyl, $-CF_3$, $-OR^6$, $-SR^6$, $-OCF_3$, -CN, $-NO_2$, $-NR^6SO_2R^7$, $-NR^6C(O)R^7$ or $-NR^6R^7$, wherein said alkyl and cycloalkyl are optionally substituted by halogen, OR^6, $-NR^6R^7$ or phenyl;

R^2 is independently H, F, Cl, methyl, ethyl, $-NHSO_2CH_3$, $-NO_2$, $-NH_2$, $-NHCOCH_3$, $-SCH_3$, -OH, $-OCH_3$;

R^3 is H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, -CN, $-OR^8$, $-SR^8$, $-NR^8R^9$, $-CF_3$, $-OCF_3$, $-NO_2$, $-C(O)R^8$, $-C(O)OR^8$, $-C(O)NR^8R^9$, $-NR^8C(O)R^9$, $-S(O)_{1-2}R^8$, $-NR^8S(O)_{1-2}R^9$, $-S(O)_{1-2}NR^8R^9$, C_3-C_6 cycloalkyl, morpholinyl, pyrrolidinonyl, oxazolidinonyl, $-CH_2$morpholinyl , pyrazolyl, triazolyl or phenyl, wherein R^3 is independently optionally substituted by 0, 1, 2 or 3 R^{10};

~~R^2 and R^3 are independently H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, $(C_0$-C_3 alkyl)CN, $(C_0$-C_3 alkyl)OR^8, $(C_0$-C_3 alkyl)SR^8, $(C_0$-C_3 alkyl)NR^8R^9, $(C_0$-C_3 alkyl)CF_3, $O(C_0$-C_3 alkyl)CF_3, $(C_0$-C_3 alkyl)NO_2, $(C_0$-C_3 alkyl)$C(O)R^8$, $(C_0$-C_3 alkyl)$C(O)OR^8$, $(C_0$-C_3 alkyl)$C(O)NR^8R^9$, $(C_0$-C_3 alkyl)$NR^8C(O)R^9$, $(C_0$-C_3 alkyl)$S(O)_{1-2}R^8$, $(C_0$-C_3~~

~~alkyl)$NR^8S(O)_{1-2}R^9$, $(C_0-C_3$ alkyl)$S(O)_{1-2}NR^8R^9$, $(C_0-C_3$ alkyl)$(C_3-C_6$ cycloalkyl),~~ morpholinyl, pyrrolidinonyl, oxazolidinonyl or $-CH_2$morpholinyl , pyrazolyl or triazolyl ~~$(C_0-C_3$ alkyl)(3-6 membered heterocyclyl), $(C_0-C_3$ alkyl)(5-6 membered heteroaryl)~~ or –(C_0-C_3 alkyl)phenyl, wherein R^2 and R^3 are independently optionally substituted by R^{10};

R^4 is $-NH_2$, –NH–, $-NR^6C(O)$–, $-NR^6C(O)O$– or $-NR^6C(O)NR^7$–;

R^5 is absent, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, phenyl, 3-7-membered heterocyclyl or 5-6-membered heteroaryl, wherein R^5 is optionally substituted by R^{10};

R^6 and R^7 are each independently H or C_1-C_3 alkyl, optionally substituted by halogen, oxo or $-NR^{11}R^{12}$; ~~or~~

~~R^6 and R^7 are independently taken together with the atom to which they are attached to form a 3-6 membered heterocyclyl, optionally substituted by halogen, oxo, $-NR^{11}R^{12}$ or C_1-C_3 alkyl;~~

R^8 and R^9 are each independently H, C_1-C_3 alkyl, C_3-C_6 cycloalkyl, phenyl, 3-6-membered heterocyclyl or 5-6-membered heteroaryl, optionally substituted by R^{10}; ~~or~~

~~R^8 and R^9 are independently taken together with the atom to which they are attached to form a 3-6 membered heterocyclyl, optionally substituted by halogen, oxo, $-NR^{11}R^{12}$ or C_1-C_3 alkyl;~~

R^{10} is independently H, oxo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, $-(C_0$-C_3 alkyl)CN, $-(C_0$-C_3 alkyl)OR^{11}, $-(C_0$-C_3 alkyl)SR^{11}, $-(C_0$-C_3 alkyl)$NR^{11}R^{12}$, $-(C_0$-C_3 alkyl)CF_3, $-(C_0$-C_3 alkyl)NO_2, $-(C_0$-C_3 alkyl)$C(O)R^{11}$, $-(C_0$-C_3 alkyl)$C(O)OR^{11}$, $-(C_0$-C_3 alkyl)$C(O)NR^{11}R^{12}$, $-(C_0$-C_3 alkyl)$NR^{11}C(O)R^{12}$, $-(C_0$-C_3 alkyl)$S(O)_{1\text{-}2}R^{11}$, $-(C_0$-C_3 alkyl)$NR^{11}S(O)_{1\text{-}2}R^{12}$, $-(C_0$-C_3 alkyl)$S(O)_{1\text{-}2}NR^{11}R^{12}$, $-(C_0$-C_3 alkyl)(C_3-C_6 cycloalkyl), $-(C_0$-C_3 alkyl)(3-6-membered heterocyclyl), $-(C_0$-C_3 alkyl)C(O)(3-6-membered heterocyclyl), $-(C_0$-C_3 alkyl)(5-6-membered heteroaryl) or $-(C_0$-C_3 alkyl)phenyl, wherein R^{10} is independently optionally substituted by halogen, C_1-C_3 alkyl, oxo, $-CF_3$, $-(C_0$-C_3 alkyl)OR^{13}, $-(C_0$-C_3 alkyl)$NR^{13}R^{14}$, $-(C_0$-C_3 alkyl)$C(O)R^{13}$ or $-(C_0$-C_3 alkyl)$S(O)_{1\text{-}2}R^{13}$;

R^{11} and R^{12} are independently H, C_1-C_6 alkyl, $-(C_0$-C_3 alkyl)(C_3-C_6 cycloalkyl), $-(C_0$-C_3 alkyl)(3-6-membered heterocyclyl), $-(C_0$-C_3 alkyl)(5-6-membered heteroaryl) or $-(C_0$-C_3 alkyl)phenyl, optionally substituted by halogen, oxo, $-OR^{13}$, $-SR^{13}$, $-NR^{13}R^{14}$, C_1-C_3 alkyl, $-(C_0$-C_3 alkyl)(C_3-C_6 cycloalkyl), $-(C_0$-C_3 alkyl)phenyl, $-(C_0$-C_3 alkyl)(3-6-membered heterocyclyl) or $-(C_0$-C_3 alkyl)(5-6-membered heteroaryl); ~~or~~

~~R^{11} and R^{12} are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl, optionally substituted by halogen, oxo, $-NR^{13}R^{14}$ or C_1-C_3 alkyl;~~

R^{13} and R^{14} are independently H, or C_1-C_6 alkyl; and, ~~OH or OCH_3, optionally substituted by halogen, $-NH_2$, $-N(CH_3)_2$, phenyl or oxo, wherein said phenyl is optionally substituted by halogen, C_1-C_6 alkyl, CF_3, $-NR^aR^b$ or OR^a or~~

~~R^{13} and R^{14} are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl, optionally substituted by halogen, oxo, $-NH_2$, $-N(CH_3)_2$ or C_1-C_3 alkyl;~~


R^{15} is H,~~; and~~


~~R^a and R^b are independently H or C_1-C_6 alkyl optionally substituted by halogen or oxo; or~~

~~R^a and R^b are taken together with the atom to which they are attached to form a 3-6 membered heterocyclyl, optionally substituted by halogen, oxo or C_1-C_3 alkyl;~~


2. The compound of claim 1, wherein both R^1 is halogen.


~~23~~. The compound of claim 1 or 2, wherein R^2 is H and R^3 is H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, –CN, $–OR^8$, $–SR^8$, $–NR^8R^9$, $–CF_3$, $–OCF_3$, $–NO_2$, $–C(O)R^8$, $–C(O)OR^8$, $–C(O)NR^8R^9$, $–NR^8C(O)R^9$, $–S(O)_{1\text{-}2}R^8$, $–NR^8S(O)_{1\text{-}2}R^9$, $–S(O)_{1\text{-}2}NR^8R^9$, C_3-C_6 cycloalkyl, morpholinyl, pyrrolidinonyl, oxazolidinonyl, –CH_2morpholinyl , pyrazolyl, triazolyl ~~3-6-membered heterocyclyl, 5-6-membered heteroaryl~~ or phenyl, wherein R^3 is optionally substituted by 0, 1, 2 or 3 R^{10}.


~~34~~. The compound of ~~any one of~~ claims ~~1 and~~ or ~~32~~, wherein the portion of Formula I having the structure:  , is selected from:



wherein the wavy lines represent the point of attachment in Formula I.

5. The compound of any one of claims 1 to 3, wherein the portion of Formula I having the structure:  , is selected from:







wherein the wavy lines represent the point of attachment in Formula I.

46. The compound of any one of claims 1-35, wherein R^5 is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, 3-7-membered heterocyclyl, phenyl, 5-6-membered heteroaryl, optionally substituted by R^{10}, and wherein R^{10} is oxo, C_1-C_6 alkyl, halogen, –CN, $–OR^{11}$, $–SR^{11}$, $–NR^{11}R^{12}$, $–CF_3$, $–C(O)R^{11}$, $–C(O)OR^{11}$, $–C(O)NR^{11}R^{12}$, $–NR^{11}C(O)R^{12}$, $–S(O)_{1-2}R^{11}$, $–NR^{11}S(O)_{1-2}R^{12}$, $–S(O)_{1-2}NR^{11}R^{12}$, C_3-C_6 cycloalkyl, 3-6-membered heterocyclyl, –C(O)(3-6-membered heterocyclyl), 5-6-membered heteroaryl or phenyl, wherein R^{10} is independently optionally substituted by halogen, C_1-C_3 alkyl, oxo, $–CF_3$, $–OR^{13}$, $–NR^{13}R^{14}$, $–C(O)R^{13}$ or $–S(O)_{1-2}R^{13}$.


47. The compound of claim 46, wherein R^5 is selected from:






wherein the wavy lines represent the point of attachment in Formula I.


~~68~~. The compound of any one of the preceding claims ~~1~~, selected from




,




,




,




,




,



,











and




















.










~~79~~. The compound of any one of claims ~~1~~ 1 to ~~71~~, selected from







Example	Structure
2	




283	
284	
285	
286	
287	
~~288~~	
290	

~~365~~	
366	
367	
368	
~~369~~	
370	
371	
372	
373	
374	



~~375~~	
376	
377	
378	
379	
380	
381	







~~383~~	
~~384~~	
385	
386	
387	
388	
389	
390	
391	

407	
408	
~~409~~	
410	
~~411~~	
412	

616	
617	
618	

10. The compound of any one of claims 1, 3, 4, 6 or 7, selected from

288	
365	

369	
375	
383	
384	
409	
411	

~~8~~11. A pharmaceutical composition comprising a compound of any one of claims 1-~~7~~10 and a pharmaceutically acceptable carrier, adjuvant or vehicle.

~~9~~12. The compound of any one of claim s 1-~~7~~10 for use as a medicament for treating psoriasis or inflammatory bowel disease.

~~10~~13. The use of a compound of any one of claims 1-~~7~~10 in the manufacture of a medicament for the treatment of immunological diseases.

* * *